ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
- DOI
- 10.1038/s43856-022-00163-y
- Published
- 2022
- Container
- Communications medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s43856-022-00163-y,
title = {ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.},
author = {Rocconi RP and Stanbery L and Tang M and Madeira da Silva L and Walter A and Monk BJ and Herzog TJ and Coleman RL and Manning L and Wallraven G and Horvath S and Bognar E and Senzer N and Brun S and Nemunaitis J},
year = {2022},
journal = {Communications medicine},
doi = {10.1038/s43856-022-00163-y},
url = {https://doi.org/10.1038/s43856-022-00163-y}
}RIS
TY - JOUR TI - ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. AU - Rocconi RP AU - Stanbery L AU - Tang M AU - Madeira da Silva L AU - Walter A AU - Monk BJ AU - Herzog TJ AU - Coleman RL AU - Manning L AU - Wallraven G AU - Horvath S AU - Bognar E AU - Senzer N AU - Brun S AU - Nemunaitis J PY - 2022 JO - Communications medicine DO - 10.1038/s43856-022-00163-y UR - https://doi.org/10.1038/s43856-022-00163-y ER -
APA
RP, R., L, S., M, T., L, M. D. S., A, W., BJ, M., TJ, H., RL, C., L, M., G, W., S, H., E, B., N, S., S, B., & J, N. (2022). ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.. Communications medicine. https://doi.org/10.1038/s43856-022-00163-y
Source records
- pubmed · retrieved 2026-09-26T21:26:24.804Z